Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALAIN BOUCHARD

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1659336790
CMS profile
210453
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,694.07

29 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $956.50 27
Travel and Lodging $737.57 2

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALAIN BOUCHARD

NPI 1659336790 · CMS profile ID 210453

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659336790?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALAIN BOUCHARD, NPI 1659336790, CMS profile ID 210453. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659336790?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ALAIN BOUCHARD, NPI 1659336790, CMS profile ID 210453. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659336790?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ALAIN BOUCHARD, NPI 1659336790, CMS profile ID 210453, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1659336790?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

29 matching records · $1,694.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 29 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–29 of 29.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer Healthcare Pharmaceuticals Inc. $19.4612/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225472634 CMS
Edwards Lifesciences Corporation $153.5012/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225278501 CMS
Alnylam Pharmaceuticals Inc. $19.9211/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212740813 CMS
Novartis Pharmaceuticals Corporation $16.8610/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200008618 CMS
Novartis Pharmaceuticals Corporation $224.9710/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200074384 CMS
Novartis Pharmaceuticals Corporation $529.5610/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200074386 CMS
Novartis Pharmaceuticals Corporation $208.0110/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200074382 CMS
Novo Nordisk Inc $25.3809/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189072584 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.4308/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222733426 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.2008/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225472632 CMS
PFIZER INC. $22.8507/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229446995 CMS
PFIZER INC. $17.6107/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229493424 CMS
E.R. Squibb & Sons, L.L.C. $15.8707/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184883711 CMS
Stryker Corporation $23.2706/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227412166 CMS
Novo Nordisk Inc $25.9106/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188759321 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.4805/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222733424 CMS
PFIZER INC. $19.2105/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229025077 CMS
E.R. Squibb & Sons, L.L.C. $6.8904/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184883681 CMS
PFIZER INC. $23.9304/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228943122 CMS
E.R. Squibb & Sons, L.L.C. $1.8504/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184883683 CMS
E.R. Squibb & Sons, L.L.C. $6.1404/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184883657 CMS
Merck Sharp & Dohme LLC $55.0003/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238028952 CMS
Novartis Pharmaceuticals Corporation $18.8702/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200008612 CMS
E.R. Squibb & Sons, L.L.C. $18.5402/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184883639 CMS
Novartis Pharmaceuticals Corporation $21.7002/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200008616 CMS
Novo Nordisk Inc $18.5002/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188223363 CMS
E.R. Squibb & Sons, L.L.C. $93.4701/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184883617 CMS
Novartis Pharmaceuticals Corporation $14.2801/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200008614 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.4101/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222733422 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,433.21 43
PY2020 $162.79 4
PY2021 $51.09 3
PY2022 $6,327.77 9
PY2023 $1,770.19 24
PY2024 $581.75 30
PY2025 $1,694.07 29

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $512,704.89 27
PY2024 Principal investigator $785,216.13 34
PY2023 Principal investigator $451,574.97 10
PY2022 Principal investigator $121,891.37 2
PY2019 Principal investigator $9,781.25 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $13,902.00 12/12/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175161650
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,415.58 12/03/2025 Covered Recipient Teaching Hospital
St Vincents Birmingham
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190297994
Principal investigator 1 Janssen Research & Development, LLC $16,019.00 11/19/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175162149
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,194.30 11/19/2025 Covered Recipient Teaching Hospital
St Vincents Birmingham
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190297998
Principal investigator 1 Janssen Research & Development, LLC $22,256.00 11/07/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175162260
Principal investigator 1 Janssen Research & Development, LLC $3,634.00 11/03/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175161674
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,922.69 10/28/2025 Non-covered Recipient Entity
BIRMINGHAM HEMATOLOGY AND ONCOLOGY ASSOCIATES
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190306641
Principal investigator 1 Amgen Inc. $22,805.14 09/24/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246638058
Principal investigator 1 Janssen Research & Development, LLC $11,128.00 09/19/2025 Covered Recipient Teaching Hospital
Ascension Seton Medical Center
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277360
Principal investigator 1 Amgen Inc. $32,623.79 09/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246638064
Principal investigator 1 Janssen Research & Development, LLC $26,092.00 08/25/2025 Covered Recipient Teaching Hospital
Ascension Seton Medical Center
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275339
Principal investigator 1 Janssen Research & Development, LLC $9,405.00 07/23/2025 Covered Recipient Teaching Hospital
Ascension Seton Medical Center
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175276565
Principal investigator 1 Janssen Research & Development, LLC $8,867.00 06/23/2025 Covered Recipient Teaching Hospital
Ascension Seton Medical Center
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277178
Principal investigator 1 Janssen Research & Development, LLC $15,483.00 06/20/2025 Covered Recipient Teaching Hospital
Ascension Seton Medical Center
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275420
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,072.00 05/29/2025 Non-covered Recipient Entity
UNIVERSITY OF ALABAMA AT BIRMINGHAM
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190298779
Principal investigator 1 Janssen Research & Development, LLC $10,381.00 05/21/2025 Covered Recipient Teaching Hospital
Ascension Seton Medical Center
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275633
Principal investigator 1 Amgen Inc. $12,408.64 04/24/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246641099
Principal investigator 1 Janssen Research & Development, LLC $17,262.00 04/23/2025 Covered Recipient Teaching Hospital
Ascension Seton Medical Center
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175276672
Principal investigator 1 Janssen Research & Development, LLC $17,502.00 03/21/2025 Covered Recipient Teaching Hospital
Ascension Seton Medical Center
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277437
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,639.00 02/27/2025 Non-covered Recipient Entity
ST VINCENTS BIRMINGHAM
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190312479
Principal investigator 1 Janssen Research & Development, LLC $30,074.00 02/19/2025 Covered Recipient Teaching Hospital
Ascension Seton Medical Center
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175276687
Principal investigator 1 Novartis Pharmaceuticals Corporation $38,471.18 02/17/2025 Covered Recipient Teaching Hospital
St Vincents Birmingham
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190295908
Principal investigator 1 Novartis Pharmaceuticals Corporation $62,165.62 01/27/2025 Covered Recipient Teaching Hospital
St Vincents Birmingham
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190295912
Principal investigator 1 Janssen Research & Development, LLC $24,436.00 01/22/2025 Covered Recipient Teaching Hospital
Ascension Seton Medical Center
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275700
Principal investigator 1 Janssen Research & Development, LLC $5,040.00 01/10/2025 Covered Recipient Teaching Hospital
Ascension Seton Medical Center
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275785
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,979.05 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190310212
Principal investigator 1 Amgen Inc. $11,526.90 01/03/2025 Non-covered Recipient Entity
ASCENSION SAINT VINCENTS BIRMINGHAM
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246639439